serum monocyte chemoattractant protein-1 in pancreatic cancer在胰腺癌血清单核细胞化学引诱物蛋白1.pdf

Hindawi Publishing Corporation Journal of Oncology Volume 2011, Article ID 518394, 6 pages doi:10.1155/2011/518394 Research Article Serum Monocyte Chemoattractant Protein-1 in Pancreatic Cancer Jennifer Sullivan,1 Qiaoke Gong,1 Terry Hyslop,2 Harish Lavu,1 Galina Chipitsyna,1 Charles J. Yeo,1 and Hwyda A. Arafat1, 3 1 Department of Surgery and Jeff erson Pancreatic, Biliary and Related Cancer Center, Thomas Jeff erson University, Philadelphia, PA 19107, USA 2 Department of Pharmacology and Experimental Therapeutics, Thomas Jeff erson University, Philadelphia, PA 1015, USA 3 Department of Pathology Anatomy and Cell Biology, Thomas Jeff erson University, Philadelphia, PA 1015, USA Correspondence should be addressed to Hwyda A. Arafat, hwyda.arafat@jeff Received 25 March 2011; Revised 28 July 2011; Accepted 2 August 2011 Academic Editor: Judith A. Smith Copyright © 2011 Jennifer Sullivan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background/Aims. Pancreatic ductal adenocarcinoma (PDA) has etiological association with chronic inflammation. Elevated circu- lating levels of inflammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1), are found in obese individuals. We hypothesized that serum MCP-1 levels are elevated in obese PDA patients. Methods. ELISA was used to analyze MCP-1 serum levels in PDA (n = 62) and intraductal papillary mucinous neoplasms (IPMN) (n = 27). Recursive partitioning statistical analysis investigated the relationship between log MCP-1 and clinicopathological parameters. Results. Log MCP-1 values were significantly (P 0.05) elevated